[go: up one dir, main page]

PE20020485A1 - Derivados de quinolina y quinazolina como antagonistas del neuropeptido y - Google Patents

Derivados de quinolina y quinazolina como antagonistas del neuropeptido y

Info

Publication number
PE20020485A1
PE20020485A1 PE2001000891A PE2001000891A PE20020485A1 PE 20020485 A1 PE20020485 A1 PE 20020485A1 PE 2001000891 A PE2001000891 A PE 2001000891A PE 2001000891 A PE2001000891 A PE 2001000891A PE 20020485 A1 PE20020485 A1 PE 20020485A1
Authority
PE
Peru
Prior art keywords
alkyl
quinoline
trifluoroalkyl
quinazoline derivatives
alcoxyl
Prior art date
Application number
PE2001000891A
Other languages
English (en)
Inventor
Volker Breu
Frank Dautzenberg
Philippe Guerry
Philippe Pflieger
Matthias Heinrich Nettekoven
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020485A1 publication Critical patent/PE20020485A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A DERIVADOS DE QUINOLINA Y QUINAZOLINA DE FORMULA I DONDE R1 ES ALQUILO, CICLOALQUILO, ARALQUILO, TRIFLUOROALQUILO; R2 ES H, ALQUILO, ALCOXILO, HIDROXILO, HALOGENO, TRIFLUOROALQUILO, DIFLUOROALQUILO, TRIFLUOROALQUILO; R3 ES ARILO, HETEROARILO; R4 ES H, R5 ES H, ALQUILO, ARALQUILO; R6 Y R7 SON H, ALQUILO; A1 ES CH, N; A2 ES UN ANILLO HETEROCICLO DE 4-10 MIEMBROS SUSTITUIDO CON ALQUILO, OH, ALCOXILO, ALCOXIALQUILO, COOR5, CONR6R7, ENTRE OTROS; SON COMPUESTOS PREFERIDOS 7-(3-CLORO-FENIL)-2-METIL-4-PIRROLIDIN-1-IL-QUINOLINA; 2-METIL-4-PIRROLIDIN-1-IL-7-(3-TRIFLUOROMETIL-FENIL)-QUINOLINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y AL USO CON UN INHIBIDOR DE LIPASAS COMO ORLISTAT. LOS COMPUESTOS SON ANTAGONISTAS DEL NEUROPEPTIDO Y; PUEDEN SER UTILES PARA EL TRATAMIENTO DE ARTRITIS, ENFERMEDADES CARDIOVASCULARES, DIABETES, INSUFICIENCIA RENAL, TRASTORNOS ALIMENTARIOS, OBESIDAD
PE2001000891A 2000-09-06 2001-09-05 Derivados de quinolina y quinazolina como antagonistas del neuropeptido y PE20020485A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00119262 2000-09-06

Publications (1)

Publication Number Publication Date
PE20020485A1 true PE20020485A1 (es) 2002-06-14

Family

ID=8169763

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000891A PE20020485A1 (es) 2000-09-06 2001-09-05 Derivados de quinolina y quinazolina como antagonistas del neuropeptido y

Country Status (16)

Country Link
US (2) US6900226B2 (es)
EP (1) EP1318981A2 (es)
JP (1) JP2004508357A (es)
KR (1) KR100621272B1 (es)
CN (1) CN1274676C (es)
AR (1) AR030596A1 (es)
AU (2) AU1047402A (es)
BR (1) BR0113710A (es)
CA (1) CA2420703A1 (es)
GT (1) GT200100183A (es)
MX (1) MXPA03001928A (es)
PA (1) PA8528401A1 (es)
PE (1) PE20020485A1 (es)
UY (1) UY26926A1 (es)
WO (1) WO2002020488A2 (es)
ZA (1) ZA200301719B (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE387428T1 (de) 2001-05-21 2008-03-15 Hoffmann La Roche Chinolinderivate als liganden für den neuropeptid-y-rezeptor
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AU2002332054B2 (en) * 2001-09-24 2007-11-08 Imperial Innovations Limited Modification of feeding behavior
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
KR100659428B1 (ko) * 2002-02-04 2006-12-19 에프. 호프만-라 로슈 아게 Ｎｐｙ 길항제로서의 퀴놀린 유도체
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
CN1665791A (zh) 2002-07-05 2005-09-07 霍夫曼-拉罗奇有限公司 喹唑啉衍生物
CA2493712A1 (en) 2002-08-07 2004-02-19 F. Hoffmann-La Roche Ag Aminothiazole derivatives as npy5 receptor inhibitors
EP1571146A4 (en) * 2002-12-10 2010-09-01 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1601357A4 (en) * 2003-03-10 2007-10-03 Schering Corp HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
JP4887139B2 (ja) * 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
CA2535619A1 (en) 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CA2551037A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
CA2545340A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
CN102127057A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US7718658B2 (en) * 2004-09-02 2010-05-18 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US8283354B2 (en) * 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
AU2005304040B2 (en) * 2004-11-09 2009-04-23 F. Hoffmann-La Roche Ag Aminoquinazolines compounds
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
BRPI0610580B8 (pt) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd composto derivado de piperidina
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
CA2621470A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
EP1942898B2 (en) 2005-09-14 2014-05-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
CA2627139A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
BRPI0618354B8 (pt) 2005-11-10 2021-05-25 Banyu Pharma Co Ltd composto e seu uso, composição farmacêutica, preventivo ou remédio
JP2010501593A (ja) * 2006-08-24 2010-01-21 セレネックス， インコーポレイテッド イソキノリン、キナゾリンおよびフタラジン誘導体
US8027888B2 (en) * 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2008047544A1 (en) 2006-09-28 2008-04-24 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2008120653A1 (ja) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. インドールジオン誘導体
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US20110015181A1 (en) 2008-03-06 2011-01-20 Makoto Ando Alkylaminopyridine derivative
EP2272841A1 (en) 2008-03-28 2011-01-12 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
TW201018682A (en) 2008-09-25 2010-05-16 Kyorin Seiyaku Kk Heterocyclic biaryl derivative, and pde inhibitor comprising same as active ingredient
JPWO2010041711A1 (ja) 2008-10-09 2012-03-08 杏林製薬株式会社 イソキノリン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010068414A2 (en) * 2008-11-25 2010-06-17 Bowen Richard L Methods for treating obesity related disease
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201690035A1 (ru) 2011-02-25 2016-05-31 Мерк Шарп Энд Домэ Корп. Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
PH12014500814A1 (en) 2011-11-04 2014-05-19 Hoffmann La Roche New aryl-quinoline derivatives
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
KR101415806B1 (ko) 2012-08-22 2014-07-09 한국화학연구원 퀴놀린 유도체를 포함하는 골 질환의 예방 또는 치료용 약학적 조성물
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US20180134667A1 (en) 2016-10-14 2018-05-17 TES Pharma S.r.I. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2020104456A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
CN109897874A (zh) * 2019-03-25 2019-06-18 苏州同力生物医药有限公司 一种制备手性异喹啉羧酸的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4012513A (en) * 1971-11-03 1977-03-15 Imperial Chemical Industries Limited Indole derivatives for providing analgesic and anti-inflammatory effects
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
WO1986006721A1 (en) 1985-05-07 1986-11-20 Alkaloida Vegyészeti Gyár Triazolyl quinoline derivatives
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
WO1992007844A1 (en) * 1990-11-06 1992-05-14 Pfizer Inc. Quinazolines derivatives for enhancing antitumor activity
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
KR0144833B1 (ko) * 1992-12-28 1998-07-15 김태훈 신규의 퀴나졸린 유도체 및 그의 제조방법
EP0638567A4 (en) * 1993-02-18 1995-05-10 Kyowa Hakko Kogyo Kk ADENOSINE INHIBITORS.
CA2203912A1 (en) 1995-09-01 1997-03-13 Dennis Michael Zimmerman Indolyl neuropeptide y receptor antagonists
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
CA2340052C (en) 1998-08-14 2007-05-29 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and chitosan
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
AR028782A1 (es) * 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
ATE411285T1 (de) 2000-08-10 2008-10-15 Mitsubishi Tanabe Pharma Corp Prolin-derivate und deren verwendung als medikamente
US6576644B2 (en) * 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
SE0004054D0 (sv) * 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
ATE387428T1 (de) * 2001-05-21 2008-03-15 Hoffmann La Roche Chinolinderivate als liganden für den neuropeptid-y-rezeptor
US6787558B2 (en) * 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
KR100659428B1 (ko) * 2002-02-04 2006-12-19 에프. 호프만-라 로슈 아게 Ｎｐｙ 길항제로서의 퀴놀린 유도체
EP1534681A1 (en) * 2002-06-27 2005-06-01 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
CN1665791A (zh) * 2002-07-05 2005-09-07 霍夫曼-拉罗奇有限公司 喹唑啉衍生物

Also Published As

Publication number Publication date
AU2002210474B2 (en) 2006-11-02
CA2420703A1 (en) 2002-03-14
KR100621272B1 (ko) 2006-09-13
AR030596A1 (es) 2003-08-27
JP2004508357A (ja) 2004-03-18
PA8528401A1 (es) 2002-09-30
WO2002020488A3 (en) 2002-05-16
AU1047402A (en) 2002-03-22
US20050176698A1 (en) 2005-08-11
US20020052356A1 (en) 2002-05-02
US7265125B2 (en) 2007-09-04
MXPA03001928A (es) 2003-06-19
US6900226B2 (en) 2005-05-31
CN1444563A (zh) 2003-09-24
KR20030027110A (ko) 2003-04-03
WO2002020488A2 (en) 2002-03-14
EP1318981A2 (en) 2003-06-18
UY26926A1 (es) 2002-03-22
BR0113710A (pt) 2003-06-03
ZA200301719B (en) 2004-06-22
CN1274676C (zh) 2006-09-13
GT200100183A (es) 2002-05-23

Similar Documents

Publication Publication Date Title
PE20020485A1 (es) Derivados de quinolina y quinazolina como antagonistas del neuropeptido y
PE20020667A1 (es) Derivados de piperazina como ligandos del receptor 5ht2
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
PE20021155A1 (es) Derivados de quinolina como antagonistas de neuropeptidos y
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
PE20030746A1 (es) DERIVADOS DE PIRIDO [2,1-a] ISOQUINOLINA
PE20030131A1 (es) Derivados de 6-fenildihidropirrolpirimidindiona
ATE401076T1 (de) Chinolinderivate als glucokinase liganden
PE20050664A1 (es) Derivados de 1h-imidazo[4,5-c]quinolina
PE20061093A1 (es) Piperazinas sustituidas con heterociclos con actividad antagonista de cxcr3
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
PE20060243A1 (es) Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina
CH1175401H1 (de) Piperazin Derivate verwendbar als CCR5 Antagonisten
PE20010052A1 (es) Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht
CO5611127A2 (es) Derivados de indolilmaleimida
EA200700141A1 (ru) Новые аминоциклические производные мочевины, их получение и фармацевтическое применение в качестве ингибиторов киназы
PE20010070A1 (es) COMPUESTOS DE PIRIMIDINONA COMO INHIBIDORES DE LA ENZIMA Lp-PLA2
AR060811A1 (es) Moduladores de mglur5 v
ECSP066329A (es) Derivados de pentanol heterocíclicamente sustituidos, procedimiento para su preparación y su uso como anti-inflamatorios
PE20041078A1 (es) Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh)
PE20001543A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion en terapeutica
DE60214990D1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
PE20021043A1 (es) DERIVADOS DE PIRAZINO[1,2-a]INDOL COMO AGONISTAS DEL RECEPTOR 5HT2
AR029400A1 (es) Derivados de isoxazolcarboxamida, un metodo para su preparacion y una composicion farmaceutica que los comprende

Legal Events

Date Code Title Description
FA Abandonment or withdrawal